Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes

被引:4
作者
de Graaf, J. Frederique [1 ]
van Nieuwkoop, Stefan [1 ]
Bestebroer, Theo [1 ]
Groeneveld, Daphne [1 ]
van Eijck, Casper H. J. [2 ]
Fouchier, Ron A. M. [1 ]
van den Hoogen, Bernadette G. [1 ]
机构
[1] Erasmus MC, Virosci Dept, Rotterdam, Netherlands
[2] Erasmus MC, Dept Surg, Rotterdam, Netherlands
来源
PLOS ONE | 2022年 / 17卷 / 02期
关键词
FUSION PROTEIN; CLEAVAGE SITE; INTERFERON; PATHOGENICITY; REPLICATION; DETERMINANT; EXPRESSION; INDUCTION; VIRULENCE; ALPHA;
D O I
10.1371/journal.pone.0263707
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Newcastle Disease Virus (NDV) is an avian RNA virus, which was shown to be effective and safe for use in oncolytic viral therapy for several tumour malignancies. The presence of a multi basic cleavage site (MBCS) in the fusion protein improved its oncolytic efficacy in vitro and in vivo. However, NDV with a MBCS can be virulent in poultry. We aimed to develop an NDV with a MBCS but with reduced virulence for poultry while remaining effective in killing human tumour cells. To this end, the open reading frame of the V protein, an avian specific type I interferon antagonist, was disrupted by introducing multiple mutations. NDV with a mutated V gene was attenuated in avian cells and chicken and duck eggs. Although this virus still killed tumour cells, the efficacy was reduced compared to the virulent NDV. Introduction of various mutations in the fusion (F) and hemagglutinin-neuraminidase (HN) genes slightly improved this efficacy. Taken together, these data demonstrated that NDV with a MBCS but with abrogation of the V protein ORF and mutations in the F and HN genes can be safe for evaluation in oncolytic viral therapy.
引用
收藏
页数:19
相关论文
共 36 条
[1]   Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy [J].
Buijs, P. R. A. ;
van Amerongen, G. ;
van Nieuwkoop, S. ;
Bestebroer, T. M. ;
van Run, P. R. W. A. ;
Kuiken, T. ;
Fouchier, R. A. M. ;
van Eijck, C. H. J. ;
van den Hoogen, B. G. .
CANCER GENE THERAPY, 2014, 21 (11) :463-471
[2]   Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection [J].
Buijs, P. R. A. ;
van Eijck, C. H. J. ;
Hofland, L. J. ;
Fouchier, R. A. M. ;
van den Hoogen, B. G. .
CANCER GENE THERAPY, 2014, 21 (01) :24-30
[3]   Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma [J].
Buijs, Pascal ;
van Nieuwkoop, Stefan ;
Vaes, Vincent ;
Fouchier, Ron ;
van Eijck, Casper ;
van den Hoogen, Bernadette .
VIRUSES-BASEL, 2015, 7 (06) :2980-2998
[4]   Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro [J].
Burke, Shannon ;
Shergold, Amy ;
Elder, Matthew J. ;
Whitworth, Justine ;
Cheng, Xing ;
Jin, Hong ;
Wilkinson, Robert W. ;
Harper, James ;
Carroll, Danielle K. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (06) :1015-1027
[5]   Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy [J].
Cheng, Xing ;
Wang, Weijia ;
Xu, Qi ;
Harper, James ;
Carroll, Danielle ;
Galinski, Mark S. ;
Suzich, JoAnn ;
Jin, Hong .
JOURNAL OF VIROLOGY, 2016, 90 (11) :5343-5352
[6]   Armed oncolytic viruses: A kick-start for anti-tumor immunity [J].
de Graaf, J. F. ;
de Vor, L. ;
Fouchier, R. A. M. ;
van den Hoogen, B. G. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2018, 41 :28-39
[7]   Virulence of Newcastle diseasevirus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein [J].
de Leeuw, OS ;
Koch, G ;
Hartog, L ;
Ravenshorst, N ;
Peeters, BPH .
JOURNAL OF GENERAL VIROLOGY, 2005, 86 :1759-1769
[8]   Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death [J].
Elankumaran, Subbiah ;
Rockemann, Daniel ;
Samal, Siba K. .
JOURNAL OF VIROLOGY, 2006, 80 (15) :7522-7534
[9]   Characterization of a recombinant Newcastle disease virus expressing the green fluorescent protein [J].
Engel-Herbert, I ;
Werner, O ;
Teifke, JP ;
Mebatsion, T ;
Mettenleiter, TC ;
Römer-Oberdörfer, A .
JOURNAL OF VIROLOGICAL METHODS, 2003, 108 (01) :19-28
[10]   Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity [J].
Fournier, Philippe ;
Arnold, Annette ;
Wilden, Holger ;
Schirrmacher, Volker .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 40 (03) :840-850